Literature DB >> 21094682

Abdominal pain in Irritable Bowel Syndrome: a review of putative psychological, neural and neuro-immune mechanisms.

Sigrid Elsenbruch1.   

Abstract

Chronic abdominal pain is a common symptom of great clinical significance in several areas of medicine. In many cases no organic cause can be established resulting in the classification as functional gastrointestinal disorder. Irritable Bowel Syndrome (IBS) is the most common of these conditions and is considered an important public health problem because it can be disabling and constitutes a major social and economic burden given the lack of effective treatments. IBS aetiology is most likely multi-factorial involving biological, psychological and social factors. Visceral hyperalgesia (or hypersensitivity) and visceral hypervigilance, which could be mediated by peripheral, spinal, and/or central pathways, constitute key concepts in current research on pathophysiological mechanisms of visceral hyperalgesia. The role of central nervous system mechanisms along the "brain-gut axis" is increasingly appreciated, owing to accumulating evidence from brain imaging studies that neural processing of visceral stimuli is altered in IBS together with long-standing knowledge regarding the contribution of stress and negative emotions to symptom frequency and severity. At the same time, there is also growing evidence suggesting that peripheral immune mechanisms and disturbed neuro-immune communication could play a role in the pathophysiology of visceral hyperalgesia. This review presents recent advances in research on the pathophysiology of visceral hyperalgesia in IBS, with a focus on the role of stress and anxiety in central and peripheral response to visceral pain stimuli. Together, these findings support that in addition to lower pain thresholds displayed by a significant proportion of patients, the evaluation of pain appears to be altered in IBS. This may be attributable to affective disturbances, negative emotions in anticipation of or during visceral stimulation, and altered pain-related expectations and learning processes. Disturbed "top-down" emotional and cognitive pain modulation in IBS is reflected by functional and possibly structural brain changes involving prefrontal as well as cingulate regions. At the same time, there is growing evidence linking peripheral and mucosal immune changes and abdominal pain in IBS, supporting disturbed peripheral pain signalling. Findings in post-infectious IBS emphasize the interaction between centrally-mediated psychosocial risk factors and local inflammation in predicting long-term IBS symptoms. Investigating afferent immune-to-brain communication in visceral hyperalgesia as a component of the sickness response constitutes a promising future research goal.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21094682     DOI: 10.1016/j.bbi.2010.11.010

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  88 in total

Review 1.  Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Neural and neuro-immune mechanisms of visceral hypersensitivity in irritable bowel syndrome.

Authors:  Bin Feng; Jun Ho La; Erica S Schwartz; G F Gebhart
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-03-08       Impact factor: 4.052

2.  Visceral analgesia induced by acute and repeated water avoidance stress in rats: sex difference in opioid involvement.

Authors:  M Larauche; A Mulak; Y S Kim; J Labus; M Million; Y Taché
Journal:  Neurogastroenterol Motil       Date:  2012-07-09       Impact factor: 3.598

Review 3.  [Visceral pain].

Authors:  S Elsenbruch; W Häuser; W Jänig
Journal:  Schmerz       Date:  2015-10       Impact factor: 1.107

4.  Canadian Digestive Health Foundation Public Impact Series 3: irritable bowel syndrome in Canada. Incidence, prevalence, and direct and indirect economic impact.

Authors:  Richard N Fedorak; Stephen J Vanner; William G Paterson; Ron J Bridges
Journal:  Can J Gastroenterol       Date:  2012-05       Impact factor: 3.522

5.  Global Cytokine Profiles and Association With Clinical Characteristics in Patients With Irritable Bowel Syndrome.

Authors:  Sean M P Bennet; Annikka Polster; Hans Törnblom; Stefan Isaksson; Sandrine Capronnier; Aurore Tessier; Boris Le Nevé; Magnus Simrén; Lena Öhman
Journal:  Am J Gastroenterol       Date:  2016-06-07       Impact factor: 10.864

Review 6.  Overlap of functional heartburn and gastroesophageal reflux disease with irritable bowel syndrome.

Authors:  Nicola de Bortoli; Irene Martinucci; Massimo Bellini; Edoardo Savarino; Vincenzo Savarino; Corrado Blandizzi; Santino Marchi
Journal:  World J Gastroenterol       Date:  2013-09-21       Impact factor: 5.742

7.  Supporting Patient-Provider Collaboration to Identify Individual Triggers using Food and Symptom Journals.

Authors:  Jessica Schroeder; Jane Hoffswell; Chia-Fang Chung; James Fogarty; Sean Munson; Jasmine Zia
Journal:  CSCW Conf Comput Support Coop Work       Date:  2017-02-25

8.  TummyTrials: A Feasibility Study of Using Self-Experimentation to Detect Individualized Food Triggers.

Authors:  Ravi Karkar; Jessica Schroeder; Daniel A Epstein; Laura R Pina; Jeffrey Scofield; James Fogarty; Julie A Kientz; Sean A Munson; Roger Vilardaga; Jasmine Zia
Journal:  Proc SIGCHI Conf Hum Factor Comput Syst       Date:  2017-05-02

9.  Comparison of Electroacupuncture and Mild-Warm Moxibustion on Brain-Gut Function in Patients with Constipation-Predominant Irritable Bowel Syndrome: A Randomized Controlled Trial.

Authors:  Ji-Meng Zhao; Jin-Hua Lu; Xiao-Jun Yin; Lu-Yi Wu; Chun-Hui Bao; Xing-Kui Chen; Yue-Hua Chen; Wei-Jun Tang; Xiao-Ming Jin; Huan-Gan Wu; Yin Shi
Journal:  Chin J Integr Med       Date:  2018-05-11       Impact factor: 1.978

10.  Conditioned pain modulation in women with irritable bowel syndrome.

Authors:  Monica E Jarrett; Robert J Shulman; Kevin C Cain; Wimon Deechakawan; Lynne T Smith; Philippe Richebé; Margaret Eugenio; Margaret M Heitkemper
Journal:  Biol Res Nurs       Date:  2014-01-24       Impact factor: 2.522

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.